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Objectives: Endovascular treatment for acute ischemic stroke 
with a large vessel occlusion was recently shown to be effective. 
We aimed to develop a score capable of predicting large vessel 
occlusion eligible for endovascular treatment in the early hospital 
management.
Design: Retrospective, cohort study.
Setting: Two tertiary, Swiss stroke centers.
Patients: Consecutive acute ischemic stroke patients (1,645 
patients; Acute STroke Registry and Analysis of Lausanne regis-
try), who had CT angiography within 6 and 12 hours of symptom 
onset, were categorized according to the occlusion site. Demo-
graphic and clinical information was used in logistic regression 
analysis to derive predictors of large vessel occlusion (defined as 
intracranial carotid, basilar, and M1 segment of middle cerebral 
artery occlusions). Based on logistic regression coefficients, an 
integer score was created and validated internally and externally 
(848 patients; Bernese Stroke Registry).
Interventions: None.
Measurements and Main Results: Large vessel occlusions were 
present in 316 patients (21%) in the derivation and 566 (28%) in 
the external validation cohort. Five predictors added significantly 
to the score: National Institute of Health Stroke Scale at admis-
sion, hemineglect, female sex, atrial fibrillation, and no history of 
stroke and prestroke handicap (modified Rankin Scale score, < 2). 
Diagnostic accuracy in internal and external validation cohorts was 
excellent (area under the receiver operating characteristic curve, 
0.84 both). The score performed slightly better than National 
Institute of Health Stroke Scale alone regarding prediction error 
(Wilcoxon signed rank test, p < 0.001) and regarding discrimina-
tory power in derivation and pooled cohorts (area under the receiver 
operating characteristic curve, 0.81 vs 0.80; DeLong test, p = 0.02).
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Conclusions: Our score accurately predicts the presence of emer-
gent large vessel occlusions, which are eligible for endovascular 
treatment. However, incorporation of additional demographic and 
historical information available on hospital arrival provides minimal 
incremental predictive value compared with the National Institute 
of Health Stroke Scale alone. (Crit Care Med 2016; XX:00–00)
Key Words: cerebral revascularization; endovascular procedure; 
intracranial arterial disease; stroke
Recently, the clinical benefit of endovascular revascular-ization therapy has been established by randomized, controlled trials for patients with an acute ischemic 
stroke (AIS) and a large vessel occlusion (LVO) (1–3). These 
emergent LVOs are well-known predictors of poor outcome 
(4–7), and rapid revascularization remains a primordial fac-
tor to improve clinical outcome (8, 9). In the continuum of 
prehospital triage, choice of treatment center and revascular-
ization method, and early intensive stroke unit care, the appro-
priate decisions should be based on rational choices (10). 
These will be best realized by a multidisciplinary stroke team 
composed of an well-organized emergency medical system 
and physicians, diagnostic and interventional neuroradiologic 
expertise, and neurovascular intensive care teams (11).
So far, only time from onset to angiography, stroke sever-
ity (measured by National Institute of Health Stroke Scale 
[NIHSS]), and stroke classification by the Oxford Community 
Stroke Project clinical classification were found to predict LVO 
(12–16). A large arterial occlusion on angiography was found 
in approximately 80% of patients with baseline NIHSS score 
of more than 8–10, especially in anterior circulation strokes 
and within the first hours of symptom onset (8, 12). Given that 
sensitivities of the NIHSS score cutoffs are rather low (17) and 
their validity decreases with increasing time from symptom 
onset to clinical evaluation, we sought to identify other predic-
tors (18). Additional demographic and clinical predictors for 
the presence of LVO eligible for endovascular treatment (EVT) 
are, therefore, needed to develop a preclinical triage tool.
PATIENTS AND METHODS
Study Design and Patient Selection
The scoring tool was derived from a cohort of consecutive AIS 
patients of the Acute STroke Registry and Analysis of Laus-
anne (ASTRAL) (19). For the current analysis, we selected all 
ASTRAL patients from January 2003 to July 2012 with acute 
CT angiography (CTA) performed within 12 hours after last 
seen well. CTA is performed in all patients without iodized 
contrast contraindications, such as known allergy or known 
renal failure. In the original ASTRAL article, 78% of all isch-
emic strokes had a CTA on arrival (19). The 12-hour time 
limit was based on a recent publication of the Diffusion and 
Perfusion Imaging Evaluation for Understanding Stroke-2 
investigators where they identified a maximal therapeutic time 
window of 12 hours for patients with a target mismatch (20). 
The derived predictive score was validated externally in an 
independent cohort from the Bernese Stroke Registry (January 
2004 to August 2012) (16).
For the current study, only variables assessable in the pre-
hospital phase were selected, that is, demographics, cardiovas-
cular risk factors, comorbidities, prestroke medication, type 
of clinical deficit, NIHSS and all its individual items, onset-
to-admission delay, and physiologic values (blood pressure, 
heart rate, temperature, and glucose). The initial, total NIHSS 
score was performed by NIHSS-certified stroke physicians or 
was supervised by such. In addition, the NIHSS subitems were 
dichotomized into the presence or absence of the neurologic 
deficit. The clinical sign “hemineglect” was used according to 
the NIHSS definition. Stroke mechanism was categorized fol-
lowing the Evolution Study 2, “Trial of Org 10172 in Acute 
Stroke Treatment” classification, and dissection was added as 
a stroke mechanism.
The collection, analysis, and publication of data in ASTRAL 
and the Bernese Stroke Registry were approved by the respec-
tive ethical commissions. According to Swiss regulations, 
individualized informed consent is not required for routinely 
collected clinical and radiologic data as used in these registries.
Neuroimaging Protocol
From 2003 to November 2005, the acquisition of cerebral and 
cervical angio-CT in the derivation cohort was performed on a 
16-detector scan with a slice thickness of 1.25 mm. Thereafter, 
this scanner has been replaced by a 64-detector scan with some 
improved characteristics (e.g., slice thickness of 0.63 mm). Ini-
tial stroke MRI protocol in Bernese Stroke Registry included 
diffusion weighted imaging, T2-weighted imaging, time-of-
flight (TOF) magnetic resonance angiogram (MRA), first-pass 
gadolinium-enhanced MRA of the cervical and intracranial 
arteries, and perfusion imaging on 1.5-T MRI. Since January 
2010, fluid-attenuated inversion recovery and susceptibility-
weighted imaging (SWI) imaging have been performed on 3-T 
MRI system (Magnetom Avanto and Magnetom Verio; Sie-
mens, Erlangen, Germany).
Analysis of the arterial imaging was done by a neurora-
diologist and a vascular neurologist who were aware of the 
neurologic deficit. Occlusion was defined as absent filling of 
examined arterial segment during the initial acquisition of 
contrast medium images, and the presence and the site of LVOs 
and intra- and extracranial stenoses greater than or equal to 
50% were recorded as described previously (19). Intracranial 
occlusions in the ischemic territory were categorized according 
to their site in “large” versus “intermediate” occlusions. Large 
intracranial, endovascular treatable occlusions were defined as 
an occlusion of the basilar artery (with or without intracra-
nial vertebral artery occlusion), the intracranial carotid siphon 
including the carotid T, and the M1 segment of the middle 
cerebral artery (MCA) before its bifurcation, with and without 
ipsilateral carotid occlusion. Intermediate intracranial occlu-
sions were defined as occlusions in anterior cerebral artery (A1 
or A2 segments), peripheral MCA (M2), posterior cerebral 
artery (P1 or P2 segments), intracranial part of the vertebral 
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artery (V4), and siphon of the internal carotid artery without 
distal T occlusion; the latter two were considered “intermedi-
ate” because thrombus load and clinical symptoms are usu-
ally minor in the absence of extension into the basilar artery 
and the carotid T, respectively. M2 occlusions were considered 
“intermediate” because of the different outcome and treat-
ment strategy in comparison with M1 MCA occlusions (6, 7). 
In contrast to the exclusive use of CTA in the derivation cohort, 
either acute CTA or acute MRA were performed in the Bernese 
Stroke Registry cohort. Vascular imaging was performed dur-
ing or immediately after starting IV thrombolysis (IVT) in the 
imaging facility. It was assumed that this short delay would not 
influence arterial pathology significantly.
Statistical Analysis
Univariate comparisons between AIS patients with and without 
LVO were performed for all the variables collected. Then, major 
predictors of LVO were identified by multiple logistic regression 
analysis of all candidate variables. We aimed to build a score with 
a high discriminatory power, as measured by the area under the 
receiver operating characteristic curve (ROC) (AUC). Accord-
ingly, variable selection was done via AUC maximization, using 
multifold cross validation (MCV) in order to enhance reproduc-
ibility of the results. MCV was implemented by doing a 10-fold 
random partition of the derivation cohort. A model was built by 
leaving one part out of the fitting process and using it to calculate 
AUC, then repeating the operation leaving the next part out, and 
so on. Variables were included stepwise into the model, until no 
new variable reduced the summed AUCs (summing over the 10 
left-out parts). The random partition process was repeated 500 
times, giving rise to 500 different models. Then, the best-of-500 
model was identified via MCV as the model with the highest sum 
of AUCs over 10 new 10-fold random partitions of the deriva-
tion cohort. There was no colinearity problem in the final model 
(maximal variance inflation factor of covariates, 1.16).
Statistical analysis was performed with R statistical soft-
ware (version 2.15.1, R Core Team [2012], R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
Baseline Characteristics
During the observation period (2003–2012), 2,765 patients 
were entered in the ASTRAL registry. Of them, 1,120 (40%) 
were excluded from the analysis because vascular imaging was 
performed more than 12 hours after symptom onset (n = 672, 
24%) and/or because of a lack of a good quality CTA (n = 494; 
18%). The external validation cohort from the Bernese Stroke 
Registry contained 2,023 AIS patients between January 2004 
and August 2012. In this cohort, patients underwent MRA 
(n = 1,544, 73%), CTA (n = 519, 25%), or both (n = 47, 2%) 
within 24 hours. Of this patient sample, 1,175 patients (58%) 
were excluded because one or more of the covariates of the 
score were absent (n = 1,037, 51%), data on the vessel status 
were unavailable (n = 87, 4%), or vascular imaging was per-
formed later than 12 hours after symptom onset (n = 51, 3%). 
Comparison of data from patients excluded from the study 
shows similar patient profiles between the included and the 
radiologic and/or treatment-related excluded strokes.
The demographic and baseline characteristics of the deri-
vation and validation cohorts are described in Table 1. The 
derivation cohort (316, 21%) had a lower percentage of LVO 
than the internal validation cohort (566, 28%). As expected, 
the median NIHSS score was higher in the group of LVO than 
in the group without (17 vs six derivation cohort and 16 vs five 
validation cohort; p < 0.01). The percentages of LVO patients 
having a NIHSS score of 0–4, 5–9, 10–14, and greater than or 
equal to 15 was 2.7%, 8.3%, 32.3%, and 47.5%, respectively, 
in the derivation cohort and 4.4%, 13.8%, 43.7%, and 61.6%, 
respectively, in the validation cohort. The median time from 
symptom onset to hospital arrival in the group of patients with 
a LVO was similar in both cohorts (145 min in ASTRAL and 
124 min in Bernese Stroke Registry). Cardiac emboli were most 
frequent (n = 556, 33%), followed by atherosclerotic disease 
(n = 243, 14%), unknown etiology (n = 410, 25%), lacunar 
pathology (n = 158, 10%), dissection (n = 94, 6%), multiple 
(n = 82, 5%), and rare causes (n = 67, 4%). Cerebral imag-
ing was performed within 6 hours in most patients in ASTRAL 
(n = 1,225, 75%). In the derivation cohort, IVT alone was per-
formed in 526 patients (32%) within 4.5 hours and EVT in 
43 (3%) within 6 hours; of those, 21 were pretreated with 
IVT. In the validation cohort, IVT alone was performed in 
154 patients (18%), EVT alone in 218 (26%), and combined 
treatment in 43 (5%).
Development of the Score and Internal Validation
Our selection method identified five relevant predictors of 
LVO eligible for EVT: NIHSS at admission (odds ratio [OR]: 
1.16, uncategorized), hemineglect (OR, 2.24), the absence of 
prestroke handicap (OR, 1.62), female sex (OR, 1.50), and 
atrial fibrillation (OR, 1.38). An uncategorized NIHSS score 
seemed to be the most adequate. The discriminatory power of 
each individual variable and its added value for the score has 
been identified (Supplemental Table 1, Supplemental Digital 
Content 1, http://links.lww.com/CCM/B683).
For each covariate in the model, integer score points were 
defined according to the proportionality with the β coeffi-
cients: admission NIHSS (1 point for every 1 NIHSS point: 
0 to > 42), the absence of prestroke handicap (modified Rankin 
Scale score, ≤ 2) (3 points), hemineglect (5 points), atrial 
fibrillation historically or currently (2 points), and female sex 
(3 points) (Table 2).
Figure 1 displays the predicted probability of an LVO based 
on the score (top) and the sensitivity and positive predictive 
value (PPV) as a function of cutoff position (bottom) in the 
derivation cohort. The predicted probability of detecting an 
LVO with a score of 10, 20, 30, or 40 was 6.7%, 24.0%, 58.0%, 
and 85.8%, respectively.
External Validation of the Score
The diagnostic performance of the score in the deriva-
tion and validation cohorts is shown in Table 3 (top). The 
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discriminatory power of the score was excellent in both 
cohorts (AUC, 0.84). By maximizing the sum of sensitivities 
and PPVs in the two cohorts and imposing lower bounds on 
sensitivities and PPVs (0.8 and 0.4, respectively), a cutoff value 
of 16 was derived as having the best clinical potential. The 
rationale behind the criterion for cutoff determination is to 
miss as few treatable patients as possible (hence the sensitivity 
maximization) at the same time as minimizing the probabil-
ity that a patient identified as treatable is in fact nontreatable 
(hence the PPV maximization).
The sensitivity curves in Figures 1 and 2 are similar, but the 
PPV is generally higher in the validation cohort because of a 
higher rate of LVOs (29% in the validation cohort vs 21% in 
the derivation cohort).
TABLE 2. Predictive Score for Large Vessel Occlusion: Variables Used to Define the Score, 
With Corresponding Scoring Points
Variable OR 95% CI β Coefficient Score Point
National Institutes of Health Stroke Scale on admission (per point) 1.16 1.13–1.18 0.15 1
No prestroke handicap (modified Rankin Scale score, ≤ 2) 1.62 0.86–3.04 0.48 3
Atrial fibrillation (history or current) 1.38 1.00–1.90 0.32 2
Hemineglect 2.24 1.65–3.05 0.81 5
Female sex 1.50 1.11–2.04 0.41 3
OR = odds ratio.
TABLE 1. Baseline Characteristics and Radiologic Findings in the Derivation and Validation 
Cohorts, Dichotomized According to the Presence or the Absence of a Large Vessel 
Occlusion
Clinicoradiological Parameters
Derivation Cohort Validation Cohort
No LVO (n = 1,299) LVO (n = 346) No LVO (n = 575) LVO (n = 273)
Demographics
 Age 70 (59–79) 70 (59–79) 68 (57–77) 71 (59–79)
 Female sex (%) 491 (38) 180 (52) 398 (66) 147 (54)
Medical history (%)
 Atrial fibrillation 275 (21) 110 (32) 109 (19) 109 (40)
 Arterial hypertension 761 (59) 178 (51) 374 (65) 172 (63)
 Hypercholesterolemia 793 (59) 193 (55) 310 (54) 131 (48)
 Previous stroke or transient ischemic attack 364 (28) 67 (19) 98 (17) 25 (9)
Clinical assessment on arrival
 Onset-to-arrival time 211 (124–392) 145 (98–256) 152 (90–264) 124 (77–207)
 Baseline National Institute of Health Stroke Scale 6 (3–12) 17 (13–21) 5 (3–10) 16 (12–21)
 Decreased level of consciousness (%) 116 (9) 86 (25) 75 (13) 123 (45)
 Visual field defects (%) 375 (31) 222 (70) 155 (27) 172 (63)
Vessel occlusion site (%)
 Any vessel occlusion 380 (32) 316 (100) 259 (45) 273 (100)
 Intracranial vessel occlusion 333 (28) 316 (100) 236 (41) 273 (100)
 Anterior circulation occlusion 286 (24) 291 (92) 201 (35) 221 (81)
 Posterior circulation occlusion 83 (7) 25 (8) 46 (8) 52 (19)
LVO = large vessel occlusion.
Values are expressed as medians and interquartile range for continuous variables unless stated otherwise and as absolute counts and percentage for categorical 
variables.
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Comparison of the Score With NIHSS-Only–Based 
Prediction
The predicted probabilities of LVO, sensitivities, specificities, 
PPVs, negative predictive values, and AUCs were calculated for 
the predictive accuracy of the score and the NIHSS score to 
predict LVOs eligible for EVT. Overall, the two scores perform 
similarly in both the derivation and the validation cohorts as is 
shown in Table 3 and Figures 1 and 2. The optimal cutoff point 
for the best performance of the NIHSS, determined with the 
same criterion as for the score, was 10. In both cohorts, the pre-
dicted probabilities were in slightly better concordance with the 
observed ones based on the score than based on the NIHSS alone 
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Observed prob. of LVO
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A
10 20 30 40
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Figure 1. Actual rate and predicted probability (top) and sensitivity and positive predictive value with optimal cutoff values (bottom) of the score (A) and of National 
Institute of Health Stroke Scale (NIHSS)–based prediction (B) of the large vessel occlusion presence in the derivation cohort. MIO = major intracranial occlusion.
TABLE 3. Comparison Between the Diagnostic Accuracy of the Score (Optimal Cutoff, 16)  
and Stroke Severity by National Institutes of Health Stroke Scale–Based Prediction 







Area Under the Receiver 
 Operating Characteristic Curve
Score cutoff, 16
 ASTRAL cohort 0.84 0.68 0.41 0.94 0.84
 Validation cohort 0.84 0.71 0.54 0.92 0.84
National Institute of Health Stroke Scale cutoff, 10
 ASTRAL cohort 0.86 0.69 0.43 0.95 0.83
 Validation cohort 0.85 0.73 0.55 0.92 0.84
ASTRAL = Acute STroke Registry and Analysis of Lausanne.
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as shown by the Wilcoxon signed rank test for median of pair-
wise differences in prediction error (p < 0.001). The improve-
ment in AUC was statistically significant in the derivation cohort 
(DeLong test, p = 0.047) but not in the validation cohort. In addi-
tion, the AUC calculated in the pooled cohorts was 0.84 for the 
score and 0.83 for NIHSS alone, and this difference was signifi-
cant (DeLong test, (p = 0.011) (Supplemental Table 2, Supple-
mental Digital Content 1, http://links.lww.com/CCM/B683). 
Figure 3 shows the ROC curves for the score and for the NIHSS 
alone in the pooled cohorts.
Impact of Selected Time Windows on Score 
Performance
To evaluate the impact of the selected time window on the 
score’s performance, we assessed the diagnostic accuracy of the 
statistical model in the 0- to 6-hour and 6- to 12-hour time 
delay after symptom onset (Supplemental Fig. 1, Supplemen-
tal Digital Content 1, http://links.lww.com/CCM/B683). Fur-
thermore, we executed two additional analyses among the 0- to 
6-hour cohort and 6- to 12-hour cohort separately. In the 0- to 
6-hour cohort (n = 1,225), an optimized predictive model was 
created based on the same items as the ASTRAL occlusion score 
but with the replacement of the history of atrial fibrillation by 
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Figure 2. Actual rate and predicted probability (top) and sensitivity and positive predictive value with optimal cutoff values (bottom) of the score (A) and of National 
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Figure 3. Receiver operating characteristic (ROC) curves for the score 
and for National Institute of Health Stroke Scale (NIHSS) alone in the 
pooled cohorts.
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the absence of arterial hypertension as a risk factor. Perfor-
mance in the derivation cohort was good with an AUC of 0.84, 
which is significantly better than in an NIHSS-alone predictive 
model (AUC, 0.82; p = 0.049). In the 6- to 12-hour population 
(n = 420), the performance of the model was enhanced (AUC, 
0.88) by adding decreased vigilance and hypercholesterolemia 
to three previously used items (admission NIHSS, hemine-
glect, and the absence of arterial hypertension). Significant 
difference between this model and NIHSS-alone prediction 
was not reached in the derivation cohort (p = 0.27), partially 
because of the smaller study population. The optimal NIHSS 
cutoff for the prediction of LVOs is 10 and 8 in the 0- to 6-and 
6- to 12-hour cohorts, respectively.
DISCUSSION
This study presents the development and external validation of 
a new scoring tool, which estimates the likelihood of an LVO 
eligible for endovascular revascularization in AIS. Our goal 
was to define a new score in which we tried to maximize the 
diagnostic accuracy (calculated by AUC ROC) and manage to 
improve the NIHSS-alone–based prediction with at least 1%. 
The discriminatory power to detect LVOs is mainly driven by 
the baseline NIHSS. This confirms the relationship between the 
NIHSS score and the location of the occluded vessel as shown 
earlier by Fischer et al (12) and Heldner et al (16). Our works 
shows that the NIHSS-based occlusion prediction can statis-
tically be improved by adding four clinical variables with the 
effect of each single variable (e.g., female sex) in the statisti-
cal model being adjusted for the other variables. Sex differences 
in the rates of large intracranial vessel occlusions have been 
described in the past (21). Because women are less likely to have 
a prior stroke with a persistent neurologic deficit, a high NIHSS 
score in a woman is more likely to reflect the acute stroke sever-
ity, not the prior event. The absence of a stroke history and 
lower prestroke disability correlates with higher rates of LVO, as 
such patients more often have small vessel disease, silent strokes 
(34% vs 25%; p < 0.05 in univariate analysis), and leukoara-
iosis (29% vs 20%; p < 0.05 in univariate analysis). The presence 
of neglect is often underestimated by the NIHSS score alone 
as of the 42 possible points on the NIHSS score, 7 points are 
directly related to measurement of language and only 2 points 
are related to neglect (22). At last, cardiogenic emboli by atrial 
fibrillation is well known to be linked with LVOs (23, 24).
Improving selection of patients eligible for EVT may have a 
major impact on stroke patients’ outcome (2, 10). In the prehos-
pital phase, the clinical variables (e.g., NIHSS and hemineglect) 
are theoretically available and the stroke severity assessment 
(NIHSS) by Emergency Medical Service personnel have an excel-
lent interrater reliability (25). Still, adding these new variables to 
the NIHSS does not add clinically meaningful value, and we con-
sider that NIHSS thresholds alone, if possible adapted to the tim-
ing and circulation (16), are sufficient to make decisions in most 
situations where immediate arterial imaging is not available.
The major strength of our study is the large number of 
patients and variables included in the derivation and validation 
cohorts, which make our results more robust and generalizable. In 
contrast to the recent published prehospital scores, the included 
variables were broader selected than the NIHSS subitems (26, 
27). Second, the score was validated internally and externally and 
showed good performances in both cohorts. However, our score’s 
performances are slightly weaker than NIHSS-alone prediction 
in terms of sensitivity and specificity. Third, although noninva-
sive arterial imaging will remain superior to clinical scores for 
LVO identification, such imaging may not always be available in 
the hyperacute phase and at lower level stroke receiving facili-
ties. Furthermore, loss of time with added or repeat imaging may 
decrease substantial benefit of acute EVT (8, 28).
Several limitations apply: first, intracranial vessel occlusions 
were classified in consensus among the involved centers into 
large and intermediate arterial occlusions, mainly based on 
the anatomical location. LVOs were selected for their poorer 
outcome independently of the reperfusion treatment and for 
their accessibility by EVT (4, 6, 7). Second, a substantial per-
centage (26%) of patients from the validation cohort had to be 
excluded because of lacking data. However, comparison of data 
from patients excluded from the study showed similar patient 
profiles. Third, the observed probability of LVO fluctuates dra-
matically at an NIHSS score greater than 25 because of the rar-
ity of patients for these NIHSS values. The bad calibration of 
NIHSS for high values is unlikely to have great influence on 
AUC as the points above 25 on the calibration curve represent 
very few observations (< 5%). Fourth, our definition of LVO 
was not based on a single imaging modality in the validation 
cohort but on heterogeneous methods (CTA/MRA). However, 
several comparative studies showed that high-resolution MRI 
of the intracranial LVOs (incorporated TOF 3D, contrast-
enhanced MRA, and SWI) accurately measures the degree of 
stenosis and occlusion at least as sensitive as CTA in high-risk, 
symptomatic patients (28, 29). Furthermore, compared with 
the NIHSS-based prediction, the score may be too complex 
and time consuming. The magnitude of the improved predic-
tive accuracy may not add a clinical meaningful improvement 
of the predictive ability to warrant the extra complexity, which 
may hamper implementation in routine clinical practice. The 
score must be used in conjunction with the clinical, bedside 
judgment. Finally, data collection was performed in two ter-
tiary stroke centers during a period of more than 9 years. Any 
change over time of prehospital triage, imaging techniques 
(as mentioned in the methods section), or windows for acute 
revascularization treatments may have influenced results.
CONCLUSIONS
The new five-item score may predict the presence of an LVO 
eligible for EVT in AIS with a good predictive accuracy. How-
ever, the additional complexity involved in its calculation and 
the marginal gain over the NIHSS make the isolated use of 
NIHSS alone more attractive.
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